Monte Rosa Therapeutics (GLUE) Equity Ratio (2023 - 2025)
Monte Rosa Therapeutics (GLUE) has 3 years of Equity Ratio data on record, last reported at 0.53 in Q3 2025.
- For Q3 2025, Equity Ratio fell 18.01% year-over-year to 0.53; the TTM value through Sep 2025 reached 0.53, down 18.01%, while the annual FY2024 figure was 0.51, 13.89% down from the prior year.
- Equity Ratio reached 0.53 in Q3 2025 per GLUE's latest filing, down from 0.75 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.79 in Q1 2023 and bottomed at 0.51 in Q4 2024.
- Average Equity Ratio over 3 years is 0.66, with a median of 0.65 recorded in 2024.
- Peak YoY movement for Equity Ratio: dropped 27.5% in 2024, then grew 22.39% in 2025.
- A 3-year view of Equity Ratio shows it stood at 0.59 in 2023, then decreased by 13.89% to 0.51 in 2024, then rose by 5.21% to 0.53 in 2025.
- Per Business Quant database, its latest 3 readings for Equity Ratio were 0.53 in Q3 2025, 0.75 in Q2 2025, and 0.7 in Q1 2025.